Form 4: Alumis SVP of People and Culture Receives Significant Equity Compensation

Derrick Richardson, SVP of People and Culture at Alumis Inc., was granted 42,800 restricted stock units and options to purchase 64,200 shares of common stock.

Summary

• Derrick Richardson, SVP, People and Culture at Alumis Inc. (ALMS), received a grant of 42,800 shares of common stock in the form of Restricted Stock Units (RSUs) on July 29, 2025.
• The RSUs have a grant price of $0 and will vest 25% on August 1, 2026, with the remaining shares vesting in equal quarterly installments over the subsequent 12 quarters, contingent on continuous service.
• Richardson also received a grant of options to purchase 64,200 shares of common stock on July 29, 2025, with an exercise price of $3.95 per share.
• These stock options will vest 25% on July 29, 2026, and the remaining shares will vest in equal monthly installments over the following 36 months, subject to continuous service.
• The stock options have an expiration date of July 28, 2035.
• Following these transactions, Richardson beneficially owns 42,800 shares of common stock and 64,200 stock options.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects standard executive compensation practices, aligning management's interests with shareholders through equity grants. It does not indicate any negative operational or financial news.

Positives

• The equity grants align the interests of the Senior Vice President of People and Culture with those of the shareholders, incentivizing long-term performance and retention.
• The grants represent a standard component of executive compensation, reflecting the company's commitment to attracting and retaining key talent.

Risks

• The vesting of both the restricted stock units and stock options is subject to the Reporting Person's Continuous Service to the Issuer, meaning the grants could be forfeited if employment ceases before vesting dates.

Future Outlook

The filing does not provide a future outlook for the company's performance or strategic direction, focusing solely on an insider's equity compensation.

Industry Context

This filing represents a routine executive compensation event within the biotechnology or pharmaceutical industry, where equity grants are a common practice to incentivize and retain senior leadership.

Comparison to Industry Standards

• Equity grants to senior executives, including RSUs and stock options, are standard compensation practices across the biotechnology and pharmaceutical sectors, comparable to how companies like Moderna, BioNTech, or Regeneron Pharmaceuticals structure their executive incentives.
• The vesting schedules, typically over several years and contingent on continuous service, are consistent with industry norms designed to promote long-term commitment and performance alignment.

Stakeholder Impact

• Shareholders: The grants represent potential future dilution as shares vest and options are exercised, but also serve to align the interests of a key executive with shareholder value creation.
• Employees: While not directly impacting all employees, this grant is part of the company's overall compensation philosophy, which can influence employee morale and retention strategies.

Next Steps

• The restricted stock units will begin vesting on August 1, 2026, with subsequent quarterly installments over 12 quarters.
• The stock options will begin vesting on July 29, 2026, with subsequent monthly installments over 36 months.

Key Dates

Keywords

Alumis Inc., ALMS, Derrick Richardson, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Insider Transaction, SEC Form 4